Tacilta Helena Francisco Nhampossa
Institution: Centro de Investigação em Saúde de Manhiça (CISM)
Country of work: Mozambique
What is your motivation for engaging in HIV cure and remission research?
My career goal is to be a pediatric researcher contributing to diminishing the burden of HIV/AIDS in children in Mozambique and other developing countries. Therefore, I believe it is my duty to be up to date with the latest research on HIV and AIDS, in order to identify ways to prevent and fight this disease. The Research-for-Cure Academy is an opportunity to broaden my horizons within the field of HIV/AIDS, allowing me to think outside the box. I will take advantage of this opportunity to learn about novel trends of HIV cure.
What is your current area of research?
I am the clinical coordinator of a multicentre study aiming to monitor from birth to 2 years of age, total HIV-DNA and the viral and immunological features of early treated children (<90 days after diagnosis), in order to identify participants with excellent viral and immunological control at age two. These participants are more likely to benefit from novel therapeutic interventions to cure HIV. I am also the clinical coordinator of a study entitled Improving Maternal health by reducing Malaria in African HIV women which the objective is to evaluate the safety, tolerability and efficacy of Dihydroartemisinin-piperaquine as Intermittent preventive treatment in pregnancy for malaria prevention in HIV-infected pregnant women receiving daily cotrimoxazole prophylaxis and antiretroviral drugs.